http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
-
PAVmed (PAVM) Acquires CapNostics
-
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
-
PAVmed to Host Digital Health Virtual Investor Event
-
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner
-
PAVmed to Participate in September Investor and MedTech Conferences
-
PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results
-
PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers
-
PAVmed to Present at the 41st Annual Canaccord Genuity Growth Conference
-
PAVmed (PAVM) Appoints Aster Angagaw to its Board
-
Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
-
PAVmed to Hold Business Update Conference Call on August 12, 2021
-
CORRECTING and REPLACING PAVmed to Hold Business Update Conference Call on August 12, 2021
-
PAVmed (PAVM) Appoints Stanley N. Lapidus as VP and Board Member
-
Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors
-
PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth
-
Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors
-
PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
-
PAVmed Launches Digital Health Company Veris Health Inc.
-
PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device
-
PAVmed (PAVM) Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device
-
PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device
-
Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies
-
PAVmed Provides Business Update and First Quarter 2021 Financial Results
-
PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021
-
PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team
-
PAVmed to Hold Business Update Conference Call on May 17, 2021
-
Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
-
Global Industry Executive Debbie White Joins PAVmed Board of Directors
-
PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report
-
PAVmed to Present at the 20th Annual Needham Healthcare Conference
-
PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
-
PAVmed Retires Convertible Debt
-
PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors
-
PAVmed (PAVM) majority-owned subsidiary Lucid Diagnostics to spin-off into separate public company
-
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
-
PAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST
-
First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device
-
PAVmed to Hold Business Update Conference Call on February 22, 2021
-
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
PAVmed (PAVM) Announces Registered Direct Offering of its Common Stock
-
PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
-
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
-
PAVmed (PAVM) Prices Additional $8.1 Million Common Stock Registered Direct Offering
-
PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering
-
PAVmed (PAVM) Announces 5.6M Share Registered Direct Offering of its Common Stock Priced at $1.60/sh
-
PAVmed Announces Registered Direct Offering of its Common Stock
-
PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update
-
PAVmed to Hold Business Update Conference Call on November 17, 2020
-
PAVmed to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020

